Deals roundup: Novo boosts obesity manufacturing with Catalent buy

Novo Nordisk’s $11 billion acquisition of three fill-finish sites on two continents represents a giant step toward alleviating supply concerns around fast-selling obesity drug Wegovy semaglutide.

The two-step process began with the acquisition by Novo Holdings A/S of Catalent Inc. (NYSE:CTLT) for $63.50 per share, suggesting an enterprise value of $16.5 billion. Then, Novo Holdings sold the three sites — in Belgium, Italy and Indiana — to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO)...